Transcriptomics

Dataset Information

0

CDK4/6 inhibitor resistance in prostate cancer


ABSTRACT: CDK4/6 kinase inhibitors have shown great promise in clinical trials in various cancer types and have recently entered clinical trial for advanced prostate cancer. Although patients are expected to respond well to this class of drugs, development of resistance in some patients is anticipated. To pre-empt this and study how prostate cancer may evade CDK4/6 inhibition, new resistance models were generated from LNCaP and LAPC4 prostate cancer cells cells by prolonged culturing in presence of 0.5uM palbociclib. RNA sequencing data was integrated with phospho-proteomics to unravel the molecular underpinnings of acquired resistance to palbociclib and resultant broad CDK4/6 inhibitor resistance.

ORGANISM(S): Homo sapiens

PROVIDER: GSE99675 | GEO | 2018/05/31

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2018-05-16 | PXD006561 | Pride
2024-11-18 | E-MTAB-14085 | biostudies-arrayexpress
2019-08-23 | GSE133567 | GEO
2023-10-10 | GSE235468 | GEO
2024-01-26 | GSE253204 | GEO
2023-06-20 | PXD043133 | Pride
2020-06-30 | GSE146788 | GEO
2024-05-30 | PXD042763 | Pride
2023-04-04 | GSE223759 | GEO
2021-12-04 | GSE150997 | GEO